<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26450456</article-id><article-id pub-id-type="pmc">5063138</article-id><article-id pub-id-type="doi">10.1111/dom.12588</article-id><article-id pub-id-type="publisher-id">DOM12588</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letters</subject></subj-group></article-categories><title-group><article-title>Similar risk of exercise&#x02010;related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross&#x02010;over trial</article-title><alt-title alt-title-type="left-running-head">Heise et al.</alt-title></title-group><contrib-group><contrib id="dom12588-cr-0001" contrib-type="author" corresp="yes"><name><surname>Heise</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12588-cr-0002" contrib-type="author"><name><surname>Bain</surname><given-names>S. C.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12588-cr-0003" contrib-type="author"><name><surname>Bracken</surname><given-names>R. M.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12588-cr-0004" contrib-type="author"><name><surname>Zijlstra</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12588-cr-0005" contrib-type="author"><name><surname>Nosek</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12588-cr-0006" contrib-type="author"><name><surname>Stender&#x02010;Petersen</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12588-cr-0007" contrib-type="author"><name><surname>Rab&#x000f8;l</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12588-cr-0008" contrib-type="author"><name><surname>Rowe</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12588-cr-0009" contrib-type="author"><name><surname>Haahr</surname><given-names>H. L.</given-names></name><xref ref-type="aff" rid="dom12588-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="dom12588-aff-0001"><label><sup>1</sup></label><institution>Profil</institution><named-content content-type="city">Neuss</named-content><country country="DE">Germany</country></aff><aff id="dom12588-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Diabetes and Endocrinology Department</named-content><institution>Swansea University</institution><named-content content-type="city">Swansea</named-content><country country="GB">UK</country></aff><aff id="dom12588-aff-0003"><label><sup>3</sup></label><institution>Novo Nordisk A/S</institution><named-content content-type="city">S&#x000f8;borg</named-content><country country="DK">Denmark</country></aff><aff id="dom12588-aff-0004"><label><sup>4</sup></label><institution>Novo Nordisk Inc.</institution><named-content content-type="city">Plainsboro</named-content><named-content content-type="country-part">NJ</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Tim Heise, Profil GmbH, Hellersbergstrasse 9, 41460 Neuss, Germany.<break/>
E&#x02010;mail: <email>tim.heise@profil.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2016</year></pub-date><volume>18</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/dom.2016.18.issue-2</issue-id><fpage>196</fpage><lpage>199</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>05</day><month>10</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-18-196.pdf"/><abstract id="dom12588-abs-0001"><p id="dom12588-para-0001">We compared changes in blood glucose (<styled-content style="fixed-case">BG</styled-content>) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (<styled-content style="fixed-case">T1D</styled-content>) treated with insulin degludec (<styled-content style="fixed-case">IDeg</styled-content>) or insulin glargine (<styled-content style="fixed-case">IGlar</styled-content>) in a randomized, open&#x02010;label, two&#x02010;period, crossover trial. After individual titration and a steady&#x02010;state period, patients performed 30&#x02009;min of moderate&#x02010;intensity cycle ergometer exercise (65% peak rate of oxygen uptake). <styled-content style="fixed-case">BG</styled-content>, counter&#x02010;regulatory hormones and hypoglycaemic episodes were measured frequently during and for 24&#x02009;h after exercise. <styled-content style="fixed-case">BG</styled-content> changes during exercise were similar with <styled-content style="fixed-case">IDeg</styled-content> and <styled-content style="fixed-case">IGlar</styled-content> [estimated treatment difference (<styled-content style="fixed-case">ETD</styled-content>) for maximum <styled-content style="fixed-case">BG</styled-content> decrease: 0.14&#x02009;mmol/l; 95% confidence interval (<styled-content style="fixed-case">CI</styled-content>) &#x02212;0.15, 0.42; p&#x02009;=&#x02009;0.34], as was mean <styled-content style="fixed-case">BG</styled-content> (<styled-content style="fixed-case">ETD</styled-content> &#x02212;0.16&#x02009;mmol/l; 95% <styled-content style="fixed-case">CI</styled-content> &#x02212;0.36, 0.05; p&#x02009;=&#x02009;0.13). No hypoglycaemic episodes occurred during exercise. Post&#x02010;exercise mean <styled-content style="fixed-case">BG</styled-content>, counter&#x02010;regulatory hormone response and number of hypoglycaemic episodes in 24&#x02009;h after starting exercise were similar with <styled-content style="fixed-case">IDeg</styled-content> (18 events in 13 patients) and <styled-content style="fixed-case">IGlar</styled-content> (23 events in 15 patients). This clinical trial showed that, in patients with <styled-content style="fixed-case">T1D</styled-content> treated with a basal&#x02010;bolus regimen, the risk of hypoglycaemia induced by moderate&#x02010;intensity exercise was low with <styled-content style="fixed-case">IDeg</styled-content> and similar to that with <styled-content style="fixed-case">IGlar</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12588-kwd-0001">exercise</kwd><kwd id="dom12588-kwd-0002">glycaemic control</kwd><kwd id="dom12588-kwd-0003">insulin therapy</kwd><kwd id="dom12588-kwd-0004">type 1 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Adocia</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Astra Zeneca</funding-source></award-group></funding-group><funding-group><award-group><funding-source>BD</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Biocon</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Dance Pharmaceuticals</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Gr&#x000fc;nenthal</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Medtronic</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novartis</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanofi</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Senseonics</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Abbott</funding-source></award-group></funding-group><funding-group><award-group><funding-source>BMS</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Diartis</funding-source></award-group></funding-group><funding-group><award-group><funding-source>GlaxoSmithKline</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Johnson &#x00026; Johnson</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Merck Sharp &#x00026; Dohme</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Pfizer</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Roche</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanofi&#x02010;aventis</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Schering&#x02010;Plough</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Servier</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Takeda</funding-source></award-group></funding-group><counts><page-count count="4"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12588</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:13.10.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12588-sec-0001"><title>Introduction</title><p id="dom12588-para-0002">Physical exercise is beneficial for patients with type 1 diabetes (T1D), although associated with an increased risk of hypoglycaemia <xref rid="dom12588-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12588-bib-0002" ref-type="ref">2</xref>. Individuals with T1D lack the physiological adjustments of healthy individuals to maintain euglycaemia during physical activity <xref rid="dom12588-bib-0003" ref-type="ref">3</xref>, <xref rid="dom12588-bib-0004" ref-type="ref">4</xref>, and may avoid exercise <xref rid="dom12588-bib-0005" ref-type="ref">5</xref>. Published research and practical guidelines recommend individual adjustments to insulin dose and carbohydrate intake <xref rid="dom12588-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12588-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12588-bib-0008" ref-type="ref">8</xref>; however, variation in pharmacodynamic profiles and duration of action between different basal insulins may alter their contribution to hypoglycaemia risk. The aim of the present study was to compare changes in blood glucose (BG) concentration and hypoglycaemia risk during and after exercise in patients with T1D treated with insulin degludec (IDeg) or insulin glargine (IGlar).</p></sec><sec id="dom12588-sec-0002"><title>Methods</title><p id="dom12588-para-0003">This single&#x02010;centre, randomized, open&#x02010;label, two&#x02010;period, multiple&#x02010;dose, crossover trial complied with the Declaration of Helsinki <xref rid="dom12588-bib-0009" ref-type="ref">9</xref> and Good Clinical Practice Guidelines <xref rid="dom12588-bib-0010" ref-type="ref">10</xref>, and was approved by the local health authority and ethics committee.</p><p id="dom12588-para-0004">Healthy adults (aged 18&#x02013;45&#x02009;years, inclusive) with T1D eligible for the study had a body mass index (BMI) 18&#x02013;27&#x02009;kg/m<sup>2</sup>, glycated haemoglobin (HbA1c) level &#x02264;9.5% (80&#x02009;mmol/mol) and peak rate of oxygen uptake (VO<sub>2peak</sub>) &#x0003e;35 and &#x0003c;60&#x02009;ml O<sub>2</sub>/kg/min, and were performing regular physical cardiorespiratory activity (&#x02265;500 metabolic equivalent of task min per week <xref rid="dom12588-bib-0011" ref-type="ref">11</xref>) during the last 3&#x02009;months before screening. Exclusion criteria included cancer, cardiac diseases, supine blood pressure outside the range 90&#x02013;140&#x02009;mmHg for systolic blood pressure or 50&#x02013;90&#x02009;mmHg for diastolic blood pressure, recurrent severe hypoglycaemia or hypoglycaemic unawareness, smoking and confirmed hyperglycaemia [BG &#x02265;17&#x02009;mmol/l (&#x0223c;306&#x02009;mg/dl)] during the run&#x02010;in/steady&#x02010;state periods. Written informed consent was obtained from all patients. The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01704417).</p><p id="dom12588-para-0005">Patients were randomized to one of two treatment sequences: IDeg (Tresiba&#x000ae;, 100&#x02009;units/ml in 3&#x02010;ml prefilled investigational pens, PDS290; Novo Nordisk, Bagsv&#x000e6;rd, Denmark) followed by IGlar (Lantus&#x000ae;, 100&#x02009;units/ml in 3&#x02010;ml SoloStar&#x000ae;; Sanofi, Paris, France) or IGlar followed by IDeg. The two treatments were separated by a 7&#x02010; to 21&#x02010;day washout). Insulin aspart (IAsp) (NovoRapid&#x000ae;, 100&#x02009;units/ml in 3&#x02010;ml FlexPen&#x000ae;; Novo Nordisk, Bagsv&#x000e6;rd, Denmark) was used as bolus insulin.</p><p id="dom12588-para-0006">Treatment periods included a 14&#x02010; to 28&#x02010;day titration run&#x02010;in on each basal insulin, to reach stable glycaemic control and a prebreakfast self&#x02010;measured plasma glucose (SMPG) value of 4&#x02013;6&#x02009;mmol/l (&#x0223c;72&#x02013;108&#x02009;mg/dl). A 6&#x02010;day steady&#x02010;state period followed, during which individual doses were kept constant, standard meals were served and usual physical activity maintained to obtain a reproducible BG profile from day to day, ensuring BG was controlled before exercise [pre&#x02010;exercise BG &#x02265;5&#x02009;mmol/l (&#x0223c;90&#x02009;mg/dl) and &#x02264;10&#x02009;mmol/l (&#x0223c;180&#x02009;mg/dl); maximum difference of 2&#x02009;mmol/l (&#x0223c;36&#x02009;mg/dl) between the two exercise bouts].</p><p id="dom12588-para-0007">On day&#x02009;5 of the steady&#x02010;state period, patients' individual lunchtime IAsp doses (12:00&#x02009;hours) and carbohydrate were reduced by &#x0223c;60% (median 40&#x02009;g carbohydrate, both treatments) to achieve consistent pre&#x02010;exercise BG levels, avoiding high BG levels &#x0003e;10&#x02009;mmol/l (&#x0223c;180&#x02009;mg/dl). Three hours after lunch (15:00&#x02009;hours) patients performed a 30&#x02010;min ergometer bicycle exercise bout at 65% VO<sub>2peak</sub>. Gas exchange and heart rate were measured and %VO<sub>2peak</sub> and carbohydrate oxidation rates during exercise were calculated <xref rid="dom12588-bib-0012" ref-type="ref">12</xref>. Blood was drawn via venous cannula every 5&#x02009;min during exercise and at various time points for 22.5&#x02009;h for laboratory measurement of BG, counter&#x02010;regulatory hormones and &#x003b2;&#x02010;hydroxybutyrate. Hypoglycaemic episodes [plasma glucose &#x0003c;3.1&#x02009;mmol/l (&#x0223c;56&#x02009;mg/dl) or episodes requiring assistance of another person (nocturnal between 00:01 and 05:59&#x02009;hours, inclusive)] were recorded for 24&#x02009;h after start of exercise. Individualized corrective carbohydrate doses, adjusted at 10&#x02010;min intervals, were given as necessary.</p><p id="dom12588-para-0008">A clinically relevant treatment difference between pre&#x02010;exercise BG concentration and minimum BG concentration during exercise of 0.65&#x02009;mmol/l (&#x0223c;11.7&#x02009;mg/dl) could be detected (80% power) with a sample of 36 patients (assuming standard deviation of 1.35). BG concentration endpoints were analysed in a linear mixed model (BG concentration before exercise as covariate, treatment and period as fixed factors, and patient as a random effect). To account for unequal variances, the within&#x02010;patient variation depended on treatment. Rate of hypoglycaemia was analysed in a negative binomial regression model with a log&#x02010;link function (treatment and period as fixed factors and patient as a random effect). All other endpoints are summarized descriptively.</p></sec><sec id="dom12588-sec-0003"><title>Results</title><p id="dom12588-para-0009">Of 72 patients screened, 41 were eligible and 40 randomized (one withdrew). Thirty&#x02010;nine patients completed the trial, as one was excluded during the first run&#x02010;in (BG &#x02265;17&#x02009;mmol/l: IGlar group). The 35 men and 5 women enrolled had a mean&#x02009;&#x000b1;&#x02009;standard deviation (s.d.) age of 33.9&#x02009;&#x000b1;&#x02009;7.7&#x02009;years, BMI of 23.9&#x02009;&#x000b1;&#x02009;1.9&#x02009;kg/m<sup>2</sup>, VO<sub>2peak</sub> of 39.4&#x02009;&#x000b1;&#x02009;3.7&#x02009;ml O<sub>2</sub>/kg/min, HbA1c of 7.7&#x02009;&#x000b1;&#x02009;0.8% (61&#x02009;&#x000b1;&#x02009;9&#x02009;mmol/mol) and diabetes duration of 16.7&#x02009;&#x000b1;&#x02009;8.2&#x02009;years.</p><p id="dom12588-para-0010">The prerequisite that certain parameters were similar between the two treatments was fulfilled: basal and bolus insulin doses (Table S1), glycaemic control during steady&#x02010;state period (Figure S1), BG concentration immediately before exercise (Figure <xref rid="dom12588-fig-0001" ref-type="fig">1</xref>A), mean relative intensity during the exercise [VO<sub>2peak</sub> IDeg: 64.6&#x02009;&#x000b1;&#x02009;4.1; IGlar: 65.5&#x02009;&#x000b1;&#x02009;3.8%; (Table S2)] and pre&#x02010; and post&#x02010;exercise heart rate [&#x0223c;64 and &#x0223c;158&#x02009;bpm, respectively, with IDeg and IGlar (Figure S2)].</p><fig fig-type="Figure" xml:lang="en" id="dom12588-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Blood glucose concentration (<styled-content style="fixed-case">A</styled-content>) during 30&#x02009;min exercise and (<styled-content style="fixed-case">B</styled-content>) for up to 22.5&#x02009;h after start of exercise. Blood samples were taken frequently (every 5&#x02009;min during exercise and every 10&#x02009;min for 2.5&#x02009;h after exercise) from time 0 to 3&#x02009;h, while blood sampling time points in the remaining post&#x02010;exercise period are marked by symbols and vertical bars. <styled-content style="fixed-case">IDeg</styled-content>, insulin degludec; <styled-content style="fixed-case">IGlar</styled-content>, insulin glargine; vertical bars are standard error of the mean.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-18-196-g001"><alt-text>DOM-12588-FIG-0001-c</alt-text></graphic></fig><p id="dom12588-para-0011">During exercise, endpoints were similar with IDeg and IGlar, including decrease in BG concentration (Figure <xref rid="dom12588-fig-0001" ref-type="fig">1</xref>A), estimated maximum BG decrease [estimated treatment difference (ETD): 0.14&#x02009;mmol/l; 95% confidence interval (CI) &#x02212;0.15, 0.42 (&#x0223c;2.5&#x02009;mg/dl; 95% CI &#x02212;2.7, 7.57); p&#x02009;=&#x02009;0.34], estimated mean BG concentration [IDeg: 7.28&#x02009;mmol/l (&#x0223c;131&#x02009;mg/dl); IGlar: 7.43&#x02009;mmol/l (&#x0223c;134&#x02009;mg/dl); ETD: &#x02212;0.16&#x02009;mmol/l; 95% CI &#x02212;0.36, 0.05 (&#x0223c; &#x02212;2.9&#x02009;mg/dl; 95% CI &#x02212;6.5, 0.9); p&#x02009;=&#x02009;0.13], respiratory equivalent ratio (&#x0003e;1 for both groups) and carbohydrate oxidation [IDeg 2.9&#x02009;&#x000b1;&#x02009;0.6 and IGlar 2.8&#x02009;&#x000b1;&#x02009;0.6&#x02009;g/min (Table S2)]. There were no hypoglycaemic episodes nor requirement for carbohydrate administration during exercise.</p><p id="dom12588-para-0012">The BG concentration for 22.5&#x02009;h after start of exercise is shown in Figure <xref rid="dom12588-fig-0001" ref-type="fig">1</xref>B. Estimated mean BG concentration [IDeg: 7.12&#x02009;mmol/l (&#x0223c;128&#x02009;mg/dl); IGlar: 7.61&#x02009;mmol/l (&#x0223c;137&#x02009;mg/dl); ETD: &#x02212;0.50&#x02009;mmol/l; 95% CI &#x02212;1.14, 0.15 (&#x0223c; &#x02212;9&#x02009;mg/dl; 95% CI &#x02212;20.5, 2.7); p&#x02009;=&#x02009;0.13] and estimated minimum BG concentration [IDeg: 6.05&#x02009;mmol/l (&#x0223c;109&#x02009;mg/dl); IGlar: 6.39&#x02009;mmol/l (&#x0223c;115&#x02009;mg/dl); ETD: &#x02212;0.34&#x02009;mmol/l; 95% CI &#x02212;0.88, 0.20 (&#x0223c;6.1&#x02009;mg/dl; 95% CI &#x02212;15.9, 3.6); p&#x02009;=&#x02009;0.21] for the 2.5&#x02009;h immediately after exercise were similar between groups. Concentration of counter&#x02010;regulatory hormones and &#x003b2;&#x02010;hydroxybutyrate showed similar exercise&#x02010;related changes for IDeg and IGlar (Figure S3). The number of hypoglycaemic episodes [estimated rate ratio (ERR) 0.76 (95% CI 0.40, 1.45); p&#x02009;=&#x02009;0.39], nocturnal hypoglycaemic episodes [ERR 1.00 (95% CI 0.40, 2.47); p&#x02009;=&#x02009;1.00 (Table <xref rid="dom12588-tbl-0001" ref-type="table-wrap">1</xref>)] and carbohydrate administrations (IDeg: 32 in 14 patients; IGlar: 33 in 12 patients) for 24&#x02009;h after start of exercise were similar with IDeg and IGlar. The total mean&#x02009;&#x000b1;&#x02009;s.d. bolus insulin dose for 24&#x02009;h after start of exercise was similar (IDeg 0.29&#x02009;&#x000b1;&#x02009;0.13 and IGlar 0.33&#x02009;&#x000b1;&#x02009;0.15&#x02009;units/kg).</p><table-wrap id="dom12588-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Hypoglycaemic episodes [plasma glucose &#x02264;3.1&#x02009;mmol/l (&#x0223c;56&#x02009;mg/dl) or requiring assistance] with insulin degludec (<styled-content style="fixed-case">IDeg</styled-content>) and insulin glargine (<styled-content style="fixed-case">IGlar</styled-content>) during the 24&#x02009;h after start of exercise.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" valign="bottom" id="dom12588-ent-0004" align="left" colspan="1">Hypoglycaemic episodes</th><th colspan="2" align="left" id="dom12588-ent-0002" valign="bottom" rowspan="1">IDeg</th><th colspan="2" align="left" id="dom12588-ent-0003" valign="bottom" rowspan="1">IGlar</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12588-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">Episodes</th><th id="dom12588-ent-0006" align="left" valign="bottom" rowspan="1" colspan="1">Patients (%)</th><th id="dom12588-ent-0007" align="left" valign="bottom" rowspan="1" colspan="1">Episodes</th><th id="dom12588-ent-0008" align="left" valign="bottom" rowspan="1" colspan="1">Patients (%)</th></tr></thead><tbody valign="top"><tr><td id="dom12588-ent-0009" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemic episodes</td><td id="dom12588-ent-0010" align="left" valign="top" rowspan="1" colspan="1">18</td><td id="dom12588-ent-0011" align="left" valign="top" rowspan="1" colspan="1">13 (33.3)</td><td id="dom12588-ent-0012" align="left" valign="top" rowspan="1" colspan="1">23</td><td id="dom12588-ent-0013" align="left" valign="top" rowspan="1" colspan="1">15 (37.5)</td></tr><tr><td id="dom12588-ent-0014" align="left" valign="top" rowspan="1" colspan="1">Nocturnal hypoglycaemic episodes</td><td id="dom12588-ent-0015" align="left" valign="top" rowspan="1" colspan="1">10</td><td id="dom12588-ent-0016" align="left" valign="top" rowspan="1" colspan="1">10 (25.6)</td><td id="dom12588-ent-0017" align="left" valign="top" rowspan="1" colspan="1">10</td><td id="dom12588-ent-0018" align="left" valign="top" rowspan="1" colspan="1">9 (22.5)</td></tr></tbody></table><table-wrap-foot><fn id="dom12588-note-0001"><p>
<styled-content style="fixed-case">IDeg</styled-content>, insulin degludec; <styled-content style="fixed-case">IGlar</styled-content>, insulin glargine.</p></fn><fn id="dom12588-note-0002"><p>
<styled-content style="fixed-case">IDeg</styled-content>, n&#x02009;=&#x02009;39; <styled-content style="fixed-case">IGlar</styled-content>, n&#x02009;=&#x02009;40.</p></fn></table-wrap-foot></table-wrap><p id="dom12588-para-0013">One serious adverse event (hypoglycaemic seizure) occurred 5&#x02009;days after the IGlar period as a result of a medication error (IGlar/lispro mix&#x02010;up). No other relevant safety issues were raised.</p></sec><sec id="dom12588-sec-0004"><title>Discussion</title><p id="dom12588-para-0014">The results of the present study show that, despite different pharmacodynamic profiles and duration of action, BG concentrations during and after exercise were similar with IDeg and IGlar. No hypoglycaemic episodes occurred during exercise. The number of hypoglycaemic episodes for 24&#x02009;h after start of exercise was low and similar between IDeg and IGlar, concurring with a recent meta&#x02010;analysis of self&#x02010;reported exercise&#x02010;related hypoglycaemia with these insulins <xref rid="dom12588-bib-0013" ref-type="ref">13</xref>.</p><p id="dom12588-para-0015">In the present study, moderate&#x02010;intensity cycling increased tissue fuel requirements above those required when at rest and represented a useful model for exploring the impact of basal insulin choice concomitant with the synergistic effect of muscular contraction on carbohydrate metabolism. We observed a similarly high rate of carbohydrate oxidation (IDeg 2.9&#x02009;g/min and IGlar 2.8&#x02009;g/min) in exercising patients (Table S2). Furthermore, sub&#x02010;maximum cycling caused a significant counter&#x02010;regulatory hormone response (Figure S3), which helped to minimize BG changes from rest during the exercise period. The equivalent counter&#x02010;regulatory hormone response enabled the impact of different basal insulins to be explored. We found no differences in BG responses despite markedly different pharmacodynamic profiles of IDeg and IGlar (Figure <xref rid="dom12588-fig-0001" ref-type="fig">1</xref>).</p><p id="dom12588-para-0016">The main strength of the present study was the controlled setting to achieve similar and reasonable pre&#x02010;exercise BG concentrations that were kept within recommended limits <xref rid="dom12588-bib-0014" ref-type="ref">14</xref> with both treatments. Morning dosing ensured the highest possible insulin concentration in the circulation at the time of exercise, particularly for IGlar, with its half&#x02010;life being half that of IDeg <xref rid="dom12588-bib-0015" ref-type="ref">15</xref>.</p><p id="dom12588-para-0017">The tightly controlled setting limits the applicability of the study to a real&#x02010;life situation where patients may not adjust carbohydrate intake before exercise. This, in conjunction with a reduced bolus dose, can lead to high pre&#x02010;exercise BG <xref rid="dom12588-bib-0001" ref-type="ref">1</xref>. In addition, the experimental design did not include any reduction in post&#x02010;exercise bolus dose as this would have complicated data interpretation, although this has been shown to preserve euglycaemia and prevent hypoglycaemia <xref rid="dom12588-bib-0008" ref-type="ref">8</xref>. Finally, in the present study, we investigated only one form of exercise and further studies might usefully investigate others such as high&#x02010;intensity exercise or resistance training.</p><p id="dom12588-para-0018">In summary, this study showed that the risk of hypoglycaemia in patients with T1D induced by moderate intensity exercise was low with IDeg and similar compared with IGlar.</p></sec><sec id="dom12588-sec-0006"><title>Conflict of Interest</title><p id="dom12588-para-0020">The study was sponsored by Novo Nordisk A/S. None of the authors received any financial or monetary transfer of value for their participation in the writing of the manuscript. T. H. reports having received research funds from Adocia, Astra Zeneca, BD, Biocon, Boehringer Ingelheim, Dance Pharmaceuticals, Gr&#x000fc;nenthal, Eli Lily and Company, Medtronic, Novo Nordisk, Novartis, Sanofi and Senseonics and having received speaker honoraria and travel grants from Eli Lily and Company, Mylan and Novo Nordisk. S. C. B. reports having received honoraria, teaching and research grants from the Abbott, Astra Zeneca, Boehringer Ingelheim, BMS, Diartis, Eli Lily and Company, GlaxoSmithKline, Johnson &#x00026; Johnson, Merck Sharp &#x00026; Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi&#x02010;Aventis, Schering&#x02010;Plough, Servier and Takeda. R. B. reports having received honoraria, travel and educational grant support from, Boehringer&#x02010;Ingelheim, Eli Lily and Company, Novo Nordisk, Sanofi&#x02010;Aventis. E. Z. and L. N. have no disclosures to report. K. S.&#x02010;P., R. R., E. R. and H. L. H. are employees and shareholders in Novo Nordisk A/S.</p><p id="dom12588-para-0021">T. H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. T. H., E. Z. and L. N. conducted the study. E. R. carried out the statistical analyses. All authors were involved in the study design, contributed to the discussion of the results and reviewed and approved the manuscript.</p><p id="dom12588-para-0022">The results of this study were presented in abstract form at the World Diabetes Congress, Melbourne, Australia, 2&#x02013;6 December 2013.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12588-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Mean five&#x02010;point self&#x02010;measured plasma glucose profiles with insulin degludec and insulin glargine during the steady&#x02010;state period (the days leading up to the exercise bout).</p></caption><media xlink:href="DOM-18-196-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12588-supitem-0002"><caption><p>
<bold>Figure S2.</bold> Mean heart rate pre&#x02010;exercise and over 2&#x02010;min intervals during 30&#x02010;min exercise.</p></caption><media xlink:href="DOM-18-196-s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12588-supitem-0003"><caption><p>
<bold>Figure S3.</bold> Mean concentration of glucagon (A), cortisol (B), epinephrine (C), norepinephrine (D), growth hormone (E) and &#x003b2;&#x02010;hydroxybutyrate (F) before and after the 30&#x02010;min exercise bout.</p></caption><media xlink:href="DOM-18-196-s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12588-supitem-0004"><caption><p>
<bold>Table S1.</bold> Daily basal doses of insulin degludec and insulin glargine and daily bolus insulin doses (insulin aspart) during the steady&#x02010;state period.</p></caption><media xlink:href="DOM-18-196-s004.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12588-supitem-0005"><caption><p>
<bold>Table S2.</bold> Exercise workload, respiratory exchange ratio and carbohydrate oxidation during 30&#x02010;min exercise with insulin degludec and insulin glargine.</p></caption><media xlink:href="DOM-18-196-s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12588-sec-0005"><title>Acknowledgements</title><p id="dom12588-para-0019">We thank trial staff and participants for their participation. The authors thank Malene Wibe Poulsen (Novo Nordisk) for medical writing assistance and Mark Nelson (Watermeadow Medical) for submission assistance.</p></ack><ref-list content-type="cited-references" id="dom12588-bibl-0001"><title>References</title><ref id="dom12588-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12588-cit-0001">
<string-name>
<surname>West</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Morton</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Bain</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Bracken</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Blood glucose responses to reductions in pre&#x02010;exercise rapid&#x02010;acting insulin for 24&#x02009;h after running in individuals with type 1 diabetes</article-title>. <source>J Sports Sci</source>
<year>2010</year>; <volume>28</volume>: <fpage>781</fpage>&#x02013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">20496226</pub-id></mixed-citation></ref><ref id="dom12588-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12588-cit-0002">
<string-name>
<surname>Metcalf</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Singhvi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tsalikian</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Effects of moderate&#x02010;to&#x02010;vigorous intensity physical activity on overnight and next&#x02010;day hypoglycemia in active adolescents with type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>1272</fpage>&#x02013;<lpage>1278</lpage>.<pub-id pub-id-type="pmid">24574352</pub-id></mixed-citation></ref><ref id="dom12588-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12588-cit-0003">
<string-name>
<surname>Riddell</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Type 1 diabetes and vigorous exercise: applications of exercise physiology to patient management</article-title>. <source>Can J Diabetes</source>
<year>2006</year>; <volume>30</volume>: <fpage>63</fpage>&#x02013;<lpage>71</lpage>.</mixed-citation></ref><ref id="dom12588-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12588-cit-0004">
<string-name>
<surname>DeFronzo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Felig</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wahren</surname>
<given-names>J</given-names>
</string-name>. <article-title>Synergistic interaction between exercise and insulin on peripheral glucose uptake</article-title>. <source>J Clin Invest</source>
<year>1981</year>; <volume>68</volume>: <fpage>1468</fpage>&#x02013;<lpage>1474</lpage>.<pub-id pub-id-type="pmid">7033285</pub-id></mixed-citation></ref><ref id="dom12588-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12588-cit-0005">
<string-name>
<surname>Brazeau</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Rabasa&#x02010;Lhoret</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Strychar</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mircescu</surname>
<given-names>H</given-names>
</string-name>. <article-title>Barriers to physical activity among patients with type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2008</year>; <volume>31</volume>: <fpage>2108</fpage>&#x02013;<lpage>2109</lpage>.<pub-id pub-id-type="pmid">18689694</pub-id></mixed-citation></ref><ref id="dom12588-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12588-cit-0006">
<string-name>
<surname>Perry</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gallen</surname>
<given-names>IW</given-names>
</string-name>. <article-title>Guidelines on the current best practice for the management of type 1 diabetes, sport and exercise</article-title>. <source>Pract Diab Int</source>
<year>2009</year>; <volume>26</volume>: <fpage>116</fpage>&#x02013;<lpage>123</lpage>.</mixed-citation></ref><ref id="dom12588-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12588-cit-0007">
<string-name>
<surname>West</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Bain</surname>
<given-names>SC</given-names>
</string-name> et&#x02009;al. <article-title>A combined insulin reduction and carbohydrate feeding strategy 30&#x02010;&#x000e1;min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus</article-title>. <source>J Sports Sci</source>
<year>2010</year>; <volume>29</volume>: <fpage>279</fpage>&#x02013;<lpage>289</lpage>.</mixed-citation></ref><ref id="dom12588-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12588-cit-0008">
<string-name>
<surname>Campbell</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Trenell</surname>
<given-names>MI</given-names>
</string-name> et&#x02009;al. <article-title>Large pre&#x02010; and postexercise rapid&#x02010;acting insulin reductions preserve glycemia and prevent early&#x02010; but not late&#x02010;onset hypoglycemia in patients with type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>2217</fpage>&#x02013;<lpage>2224</lpage>.<pub-id pub-id-type="pmid">23514728</pub-id></mixed-citation></ref><ref id="dom12588-bib-0009"><label>9</label><mixed-citation publication-type="book" id="dom12588-cit-0009">
<collab collab-type="authors" id="dom12588-gp-0001">World Medical Association</collab>
. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. <article-title>Last amended by the 59th WMA General Assembly</article-title>, <publisher-loc>Seoul</publisher-loc>, <year>2008</year>.</mixed-citation></ref><ref id="dom12588-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="dom12588-cit-0010">
<collab collab-type="authors" id="dom12588-gp-0002">International Conference on Harmonisation (ICH)</collab>
<article-title>Harmonised tripartite guideline: guideline for good clinical practice E6 (R1), Step 4</article-title>. 10 June <year>1996</year>.</mixed-citation></ref><ref id="dom12588-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="dom12588-cit-0011">
<collab collab-type="authors">The IPAQ Group</collab>
. <article-title>Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)&#x000a0;&#x02013;&#x000a0;Short and Long Forms</article-title>. <year>2005</year> Available from URL: <ext-link ext-link-type="uri" xlink:href="https://docs.google.com/viewer?a=v&#x00026;pid=sites&#x00026;srcid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4OjE0NDgxMDk3NDU1YWRlZTM">https://docs.google.com/viewer?a=v&#x00026;pid=sites&#x00026;srcid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4OjE0NDgxMDk3NDU1YWRlZTM</ext-link>. Accesssed 30 October 2015.</mixed-citation></ref><ref id="dom12588-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12588-cit-0012">
<string-name>
<surname>Frayn</surname>
<given-names>KN</given-names>
</string-name>. <article-title>Calculation of substrate oxidation rates in vivo from gaseous exchange</article-title>. <source>J Appl Physiol</source>
<year>1983</year>; <volume>55</volume>: <fpage>628</fpage>&#x02013;<lpage>634</lpage>.<pub-id pub-id-type="pmid">6618956</pub-id></mixed-citation></ref><ref id="dom12588-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12588-cit-0013">
<string-name>
<surname>Heller</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Gough</surname>
<given-names>SCL</given-names>
</string-name>, <string-name>
<surname>Oyer</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Kinduryte</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Philis&#x02010;Tsimikas</surname>
<given-names>A</given-names>
</string-name>. <article-title>Exercise&#x02010;related hypoglycemia occurs at similar frequency with insulin degludec and insulin glargine (Abstract)</article-title>. <source>Diabetes</source>
<year>2013</year>; <volume>62</volume>(Suppl. 1): <fpage>A187</fpage>.</mixed-citation></ref><ref id="dom12588-bib-0014"><label>14</label><mixed-citation publication-type="book" id="dom12588-cit-0014">
<collab collab-type="authors" id="dom12588-gp-0003">American Diabetes Association</collab>
. <source>Medical Management of Type 1 Diabetes</source>. <publisher-loc>Alexandria, VA</publisher-loc>: <publisher-name>American Diabetes Association</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="dom12588-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12588-cit-0015">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>H&#x000f6;velmann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hermanski</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>B&#x000f8;ttcher</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>. <article-title>Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine</article-title>. <source>Expert Opin Drug Metab Toxicol</source>
<year>2015</year>; <volume>11</volume>: <fpage>1193</fpage>&#x02013;<lpage>1201</lpage>.<pub-id pub-id-type="pmid">26086190</pub-id></mixed-citation></ref></ref-list></back></article>